Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy

Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting....

Descripción completa

Detalles Bibliográficos
Autores principales: Ríos-Tamayo, Rafael, Martín-García, Agustín, Alarcón-Payer, Carolina, Sánchez-Rodríguez, Dolores, de la Guardia, Ana María del Valle Díaz, García Collado, Carlos Gustavo, Jiménez Morales, Alberto, Jurado Chacón, Manuel, Cabeza Barrera, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574598/
https://www.ncbi.nlm.nih.gov/pubmed/28860711
http://dx.doi.org/10.2147/DDDT.S115456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574598/
https://www.ncbi.nlm.nih.gov/pubmed/28860711
http://dx.doi.org/10.2147/DDDT.S115456

Ejemplares similares